AlphAIAlphAI — Financial news for AI agents
SEC EDGARSEP 301 min read$ABEO

Vazzano Joseph Walter sold $47K of ABEO

Vazzano Joseph Walter (Chief Financial Officer) sold 9,191 shares of ABEONA THERAPEUTICS INC. (ABEO) at $5.16 on 2026-09-29.

Original reporting
SEC EDGAR · Vazzano Joseph Walter
Published Sep 30, 2026, 1:48 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 30, 2026, 2:04 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$ABEO
Neutral
medium confidence
Mentioned
$ABEO
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ABEONeutralLow
01

Why it matters

The transaction is a routine insider sale with limited market impact.

02

Market read

Small insider sell, low trading relevance.

03

What to watch

Potential tax planning or portfolio rebalancing could drive the sale.

Relevance 3/10Novelty 3/10Timing: post-market today

Background

Form 4 filing by Abeona Therapeutics CFO discloses a modest open-market sale.

Company-level read

Ticker impact

$ABEONeutralMedium confidence
Context

CFO sold 9,191 shares for $47,385, a primary Form 4 disclosure of insider selling.

Expected impact

potential slight pressure as market prices in insider sell.

Evidence & confidence

Sale size is small relative to holdings and market cap, unlikely to move price materially.

Market effects

Sector

None significant; biotech sector unchanged.

Regional

No regional effect.

Global

Minimal global relevance.

Counterpoint

What could challenge this read

Insider sale may be routine and not indicative of future performance.

Key entities

  • Company
    Abeona Therapeutics Inc.

    Biopharma developing gene therapies.

  • Individual
    Vazzano Joseph Walter

    Chief Financial Officer of Abeona.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

ABEO insider trading history →

Related articles

SEP 26
$ABEOMed

Abeona, NexGen, Nano Nuclear, SanDisk, Tempus Trending

Analysts initiated coverage on five stocks: Abeona (ABEO) with a $17 target, NexGen (NXE) at $14, Nano Nuclear (NNE) at $33, SanDisk (SNDK) at $2,400, and Tempus (TEM) at $75. Abeona's ZEVASKYN gene therapy, NexGen's uranium project, Nano Nuclear's KRONOS reactor, SanDisk's AI infrastructure, and Tempus's diagnostics business are key focuses.

tipranks.com3 min
SEP 18
$ABEOHighAI 9/10

Abeona Therapeutics Inc.: Abeona Therapeutics Congratulates Ultragenyx on U.S. FDA Approval of FAYUVI Gene Therapy for Sanfilippo Syndrome Type A (MPS IIIA)

Abeona Therapeutics (ABEO) congratulated Ultragenyx (RARE) on FDA approval of FAYUVI, a gene therapy for Sanfilippo syndrome type A (MPS IIIA). Abeona initially developed the therapy and licensed it to Ultragenyx in 2022, making it eligible for milestone payments and royalties. FAYUVI addresses a rare, progressive neurodegenerative disease with high unmet medical need.

finanznachrichten.de2 min
AUG 13
$ABEOMed

Abeona Therapeutics Swings To Q2 Net Loss; Shares Plunge

Abeona Therapeutics (ABEO) reported Q2 2026 results showing a swing to a net loss of $20.19M, or $0.35/share, versus net income of $108.83M, or $1.71/share, a year earlier largely due to a $152.37M priority review voucher gain. Q2 revenue rose to $11.38M from $0.40M. Cash totaled $146.8M as of June 30. ZEVASKYN treated 5 patients in Q2.

rttnews.com4 min